Article Information
History
- April 24, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Rosemary E Maher1,
- Peter J Barry2,
- Edward Emmott1,
- Andrew M Jones2,3,
- Lijing Lin4,
- Paul S McNamara5,
- Jaclyn A Smith3,6 and
- Robert W Lord2,3,*
- 1Centre for Proteome Research, Department of Biochemistry & Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, UK
- 2Manchester Adult CF Centre, Manchester University NHS Foundation Trust, Southmoor Road, Wythenshawe, Manchester M23 9LT
- 3Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, M13 9PL
- 4Faculty of Biology, Medicine and Health, University of Manchester, M13 9PL
- 5Department of Child Health (University of Liverpool), Institute in the Park, Alder Hey Children’s Hospital, Eaton Rd, Liverpool, L12 2AP
- 6Department of Respiratory Medicine, Manchester University NHS Foundation Trust, Southmoor Road, Wythenshawe, Manchester M23 9LT
- ↵*Corresponding author:
Robert Lord, Manchester Adult CF Centre, Manchester University NHS Foundation Trust, Southmoor Road, Wythenshawe, Manchester M23 9LT., Email: robert.lord{at}mft.nhs.uk
Author contributions: REM, PJB, EE, AMJ, LL, PSM, JAS, RWL contributed to study concept and design; REM, PJB, EE, AMJ, LL, PSM, JAS, RWL contributed to acquisition, analysis and/or interpretation of data; REM, PJB, EE, AMJ, LL, PSM, JAS, RWL drafted the manuscript and/or provided critical input for revisions.
Posted April 24, 2023.
The influence of highly effective modulator therapies on the sputum proteome in cystic fibrosis
